NATURAL PRODUCTS

Derivatives of the Lignan 7'-Hydroxymatairesinol with Antioxidant Properties and Enhanced Lipophilicity

Thomas Moraux,[®] Stéphane Dumarçay, Philippe Gérardin, and Christine Gérardin-Charbonnier*

Laboratoire d'Études et de Recherche sur le Matériau Bois, EA4370 USC INRA, Université de Lorraine, Faculté des Sciences et Technologies, Boulevard des Aiguillettes, 54506 Vandœuvre-lès-Nancy, France

Supporting Information

ABSTRACT: The lignan 7'-hydroxymatairesinol (1), extracted from the knotwoods of fir (*Abies alba*), spruce (*Picea abies*), and Douglas fir (*Pseudotsuga menziesii*), exhibited unexpected reactivity when esterification reactions were attempted on the hydroxy group at position C-7'. To circumvent the rapid intramolecular cyclization procedure, leading quantitatively to the lignan conidendrin (7), a simple strategy for 7'-esterification of 1 under mild conditions (three steps, up to 80% overall yield) was developed. Compared to hydroxymatairesinol (1) (log $K'_w = 1.49$), the derivatives (2–5) had increased lipophilicity with log $K'_w > 3.1$, as determined by a UHPLC method. Compounds 1–5 exhibited potent antioxidant properties in the same range as the standards ascord



antioxidant properties in the same range as the standards ascorbic acid and α -tocopherol (IC₅₀ = 20-25 μ M) and higher than that of BHT using a DPPH radical-scavenging assay.

Wood is a renewable source of bioactive molecules such as lignans. These phenolic compounds show several biological properties such as antioxidant effects due to the presence of phenolic groups, as well as anti-inflammatory,^{1,2} cardiovascular,^{3,4} antiviral,^{5,6} cytotoxic,^{7–9} and enzyme inhibition effects.¹⁰ The European trees Norway spruce (*Picea abies*) and fir (*Abies alba*) have shown the presence of unconjugated lignans in higher quantities in their knotwood than in the heartwood.^{11–14} In this work, paper-mill wastes were used as a knotwood source, thus comprising a variable proportion of fir (*Abies alba*), spruce (*Picea abies*), and Douglas fir (*Pseudotsuga menziesii*). This wood was found to contain as major constituent the lignan 7'-hydroxymatairesinol (1) (30%).^{11,12,14}

The presence of a benzylic hydroxy group on C-7' is unique, providing the opportunity to produce derivatives at this position. In order to modulate the lipophilicity of compound 1, four C-7' ester derivatives (2-5) were designed. A consequent increase of solubility in lipophilic media was expected while retaining the antioxidant properties from the two guaiacyl groups (Figure 1). It can be assumed that natural antioxidants that originate from wood may find practical applications in medicinal chemistry, cosmetics, or food.

Previous reactivity studies on C-7' of hydroxymatairesinol (1) by Eklund and associates are detailed in Scheme 1. The ether 8 was prepared in alkaline conditions after treatment of 1 with sodium methoxide. However, the treatment of 1 by methylamine resulted into the lactam 9 after rearrangement during the acidic workup. Finally, these authors suggested the role of a *para*-quinone methide (pQM) (6) formed in aqueous alkaline solution as a key intermediate in the intramolecular cyclization into conidendrin (7).¹⁵



Figure 1. Esterification of 7'-hydroxymatairesinol (1) to modulate lipophilicity without altering the antioxidant guaiacyl moieties.

The work in the present investigation has explored further the reactivity of 1, prone to cyclization or rearrangement, and, as a result, circumventing these side-reactions represented a first challenge.

RESULTS AND DISCUSSION

Chemistry. The conditions of extraction from knotwoods were developed to recover 1 in large amounts.¹⁶ Hydroxy-matairesinol (1) was obtained in a 3:1 ratio of (7'S)- to (7'R)-hydroxymatairesinol, and all experiments were carried out on this constitutive mixture.

A first direct regioselective esterification with octanoic acid was attempted under Mitsunobu conditions but surprisingly did not provide the expected 7'-octanoate derivative 3 (Scheme

Received: December 6, 2016



Scheme 1. Reactivity Study on C-7' of Compound 1 (Previous Work)



2).^{17–19} The betaine resulting from the triphenylphosphine attack on diisopropyl azodicarboxylate (DIAD) was promptly formed. Nevertheless, the activation of the benzylic hydroxy group of **1** by the triphenylphosphine did not occur. The treatment of **1** with a more nucleophilic thiolate, previously formed by addition of potassium *tert*-butoxide on 1-octadecanethiol, at reflux with acetonitrile, provided the thioether **10** in moderate yield (36%). The NMR analysis confirmed the formation of **10** as the C-7' signal shifted downfield from 75.4 ppm to 52.9 ppm in the ¹³C NMR spectrum and the H-7' signal shifted from 4.63 ppm to 3.53 ppm in the ¹H NMR spectrum. No other azodicarboxylate structures were investigated to deprotonate the nucleophiles with high $pK_{a'}$ especially as the purification of **10** from the hydrazine side-product proved very challenging.

In the presence of a large excess (5 equiv) of a separately prepared thiophenolate, hydroxymatairesinol (1) rearranged into conidendrin (7). The reaction followed a SEAr-type (electrophilic aromatic substitution) mechanism, which may occur through a *para*-quinone methide intermediate (6), even though this structure has never been observed and characterized for 1. This 1,6-conjugate addition of pQM with C nucleophiles clearly benefits from the rearomatization driving force to form the guaiacyl (Scheme 3). It is worth mentioning that the 1,8-conjugate addition of the enone has never been observed.

The intramolecular cyclization also occurred in acidic conditions, and treatment of **1** with formic acid in stoichiometric conditions provided compound 7 in excellent yield.²⁰ Activation of the benzylic hydroxy by a catalytic amount of *p*-toluenesulfonic acid (PTSA) (0.1 equiv), in the presence of octanoic acid, also resulted quantitatively in the production

Scheme 3. Proposed Reaction Mechanism for the Formation of 7 in Alkaline Conditions



of 7, instead of the expected product of translactonization.²¹ Microwave heating accelerated the formation of the hypothetic tosyl intermediate (10 min at 85 °C instead of 4 h at conventional reflux) (Scheme 4). Attempting to chlorinate the benzylic hydroxy group with thionyl chloride also led to conidendrin (7) in 2 h.²²

Scheme 4. Hypothetical Intermediates Leading to Conidendrin (7) in Acidic Conditions



It appeared, therefore, that all previously described work on 4-(1-hydroxyethyl)phenol structures did not apply to 1 due to

Scheme 2. Regioselective Hydroxy Activation under Mitsunobu Conditions



DOI: 10.1021/acs.jnatprod.6b01124 J. Nat. Prod. XXXX, XXX, XXX–XXX

Table 1. Optimization of the Reaction Conditions for the Dibenzylation of Hydroxymatairesinol Guaiacyl Groups



	•		14	10			
entry	base	solvent	T, °C	time, h	results		
1	K ₂ CO ₃	DMF	rt	48	no reaction		
2	K ₂ CO ₃	choline chl./urea	80	24	traces		
3	DMAP	acetone	rt	24	12/13, 1:1, ^c no completion		
4	DMAP	acetone	reflux	24	12/13 , 1:1 ^c		
5	K_2CO_3	acetone	reflux	24	12/13 , 1:1 ^c		
6	Et ₃ N/DMAP cat ^a	acetone	reflux	24	12/13, 1:1, ^{<i>c</i>} no completion		
7	TBAB/K ₂ CO ₃	acetone	reflux	24	12, 52%		
8	TBAI/K ₂ CO ₃	acetone	reflux	24	12, 60%		
9	KI cat ^a /K ₂ CO ₃	acetone	reflux	24	12, 44%		
10	KI/K ₂ CO ₃	acetone	reflux	24	12, 46%		
11	TBAI/Cs ₂ CO ₃ ^b	acetone	reflux	1	12, 93%		
12	TBAI/Cs ₂ CO ₃ ^b	acetone	rt	4	12, 96%		
^a 0.3 equiv. ^b BnBr. ^c Yield determined by NMR spectroscopy.							

the presence of the second phenolic group in the γ -position to the hydroxy group. To remedy this issue, the development of the benzyl protection of the phenolic hydroxy groups of **1** is detailed in Table 1.

Standard conditions of phenol benzylation in dimethylformamide (DMF) with K_2CO_3 as a base did not provide any reaction (Table 1, entry 1).^{23,24} The use of a deep eutectic solvent (DES) formed by the 1:1 mixture of choline chloride and urea (Table 1, entry 2) proved not to be more efficient.²⁵ As shown with entries 4-6 (Table 1), the benzylation occurred at reflux in acetone for any base (K₂CO₃, 4-(dimethylamino)pyridine (DMAP), or Et₃N with a catalytic amount of DMAP).²⁶ However, the side-product 13 resulting from the translactonization rearrangement was also competitively formed. Indeed, the ¹³C NMR spectrum showed a partial shift for both epimers of the CHOH-7' signal to a CHOH-9' signal. For example, the (R)-epimer of 12 exhibited a CHOH-7' signal at 74.4 ppm, whereas 13 showed a CHOH-9' signal at 80.9 ppm. Reaction at room temperature with DMAP did not prevent the formation of 13 (Table 1, entry 3). In either case, the reaction was not completed after 24 h. The addition of a tetrabutylammonium salt allowed increasing the yield up to 60%, and tetrabutylammonium iodide (TBAI) proved to be slightly more effective than tetrabutylammonium bromide (TBAB) (Table 1, entries 7 and 8). The reaction mechanism involves an exchange between the iodine counterion from TBAI with chlorine from benzyl chloride, as well as a better contact between the phenolate and the benzyl chloride. Indeed, assays with KI either in catalytic or stoichiometric amounts showed lower yields compared to TBAI (Table 1, entries 9 and 10). Finally, substituting K₂CO₃ by Cs₂CO₃, and benzyl chloride by benzyl bromide, allowed the completion of the reaction at reflux in acetone in only 1 h (Table 1, entry 11).

Compound 12 was obtained at room temperature in high yield (96%) after treatment of 1 with cesium carbonate associated with TBAI (Scheme 5). The IR spectrum showed

the displacement of the phenol peak from 3420 cm^{-1} to 3500 cm^{-1} .

Scheme 5. Optimized Benzyl Protection of Compound 1



Benzylation of 1 increased its solubility in apolar solvents such as toluene. Acetate 14 was obtained in good yield (89%) after reaction of 12 with acetic anhydride in large excess (5 equiv) in the presence of NaHCO₃ as a base.²⁷ Analysis by ¹³C NMR spectroscopy was consistent with a shift of the *CH*OH-7' signal of 12 from 74.4 ppm to the *CH*OR-7' signal of 14 at 75.4 ppm (Scheme 6). The synthesis of mixed anhydrides was not explored further on longer chains.

The reaction of acyl chlorides in the presence of DMAP in acetonitrile did not produce satisfactory results, with 52% and

Scheme 6. Regioselective Acetylation of Compound 12



Scheme 7. Activation Methods for Fatty Acids







15 and **3**: $R = C_7H_{15}$, **16** and **4**: $R = C_{11}H_{23}$, **17** and **5**: $R = C_{17}H_{35}$

46% yield for the octyl and dodecanoyl chlorides, respectively (Scheme 7).²³ Compound **12** was also reacted with extemporaneously synthesized fluorooctanoyl, prepared from octanoic acid and (diethylamino)sulfur trifluoride (DAST, 1.3 equiv), to obtain **15** with an improved yield (68%).

The use of dicyclohexylcarbodiimide (DCCI) in the presence of DMAP in stoichiometric amounts provided the esters **15** and **16** in good yields (88% and 77%, respectively) (Scheme 8). IR analysis showed the appearance of two peaks for the fatty chains at 2850 and 2920 cm⁻¹.

Benzylated phenols were then deprotected with hydrogen gas at atmospheric pressure (2.5 h, 92–95%) in the presence of Pd(OH)₂ (0.3 equiv) (Scheme 8). IR analysis confirmed the recovery of the free phenols with a broad peak at 3430 cm⁻¹.

The reaction pathway was scaled up from 2 g to 3 g of starting material **1**. Satisfactorily, no variations in the yields were observed at any of the steps. The pathway did not require further scale optimization, and three long-chain esters were obtained from octanoic acid, dodecanoic acid, and octadecanoic acid.

Lipophilicity. The behavior of bioactive molecules can be strongly affected by their lipophilicities.²⁸ Also influenced are absorption, metabolism, and excretion.²⁹ A typical example would be in drug delivery, notably transport through the blood—brain barrier, requiring further pharmacokinetic and pharmacodynamic studies.³⁰ It would be expected that an increase in the lipophilicity will help the solubilization of **1** in more lipophilic conditions, as, for example, when formulated in cosmetics. Additionally, recent work has shown the improvement of antioxidant activity of hydroxytyrosol derivatives after incorporating alkylcarbonate chains of various lengths.³¹

The *n*-octanol/water partition method can be replaced by chromatographic methods.^{32,33} The partition coefficient in *n*-octanol/water (log *P*) is correlated to the retention time of the molecule in reversed-phase liquid chromatography (eq 1):^{34,35}

$$\log P = \log K - \log \frac{V_{\rm S}}{V_{\rm M}} \tag{1}$$

where V_S/V_M is the volume ratio of the stationary and mobile phase. The coefficient log K'_w is the extrapolation of log K at 100% water. It is calculated with the following expression (eq 2):

$$\log K'_{\rm w} = \log \left(\frac{t_{\rm R} - t_0}{t_0} \right) \tag{2}$$

where $t_{\rm R}$ and t_0 are, respectively, the retention times of the test compound and of the unretained compound (dead time). Therefore, log $K'_{\rm w}$ is a representative index of lipophilicity extrapolating directly the value of log *P*.

Herein, the lipophilicities of the three synthesized esters (3-5) and of natural hydroxymatairesinol (1) were determined using an isocratic elution mode with acetonitrile/water as eluent, in three different proportions to cover the lipophilicity range. The two epimers (7'R)- and (7'S)- for each ester could be separated by reversed-phase UHPLC. For any length of chain, the (7'R)-ester was consistently calculated to have a higher value of log K'_w (Table 2). Including an octyl chain on compound 1 doubled the lipophilic coefficient from 1.49 to about 3.1. The dodecanoyl and octadecanoyl chains increased the lipophilic coefficient to higher than 3.6 and 5.4, respectively.

By comparison, log *P* values for most commercially available antioxidants are very low and less than zero as for ascorbic acid (-2.15). Only a few antioxidants exhibit a higher lipophilicity, such as octyl gallate (4.1) and 2,6-di-*tert*-butyl-4-methylphenol (BHT) (5.1). Figure 2 shows the increase of lipophilicity for the (7'S)-ester family of hydroxymatairesinol (1).

Antioxidant Activity. The antioxidant activities of 1 and esters 3-5 were evaluated by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging method and compared to those of ascorbic acid, α -tocopherol, and BHT. The reaction conditions were set with equivalent volumes (1 mL) of the DPPH solution

Table 2. Lipophilicities and Antioxidant Activities of 1 andEster Derivatives 3–5

		IC ₅₀		
compound	$\log {K'}_{\rm w}$	(µM)	$(mg \cdot L^{-1})$	
1	1.49 ^{<i>a</i>}	20.0 ± 0.1	7.49	
3	3.06/3.12 ^b	24.1 ± 0.1	12.06	
4	3.63/3.68 ^b	24.5 ± 0.1	13.64	
5	5.43/5.50 ^b	25.2 ± 0.1	16.15	
ascorbic acid	-2.15°	20.3 ± 0.1	3.58	
		12.6 ± 0.2^{d}	2.22 ^d	
citric acid	-1.7^{c}	nt ^e	nt ^e	
octyl gallate	4.1 ^c	nt ^e	nt ^e	
α -(\pm)-tocopherol		23.5 ± 0.1	10.12	
BHT	5.1 ^c	34.0 ± 0.3	7.49	

^{*a*}A single peak was obtained under UHPLC conditions. ${}^{b}(7'S)/(7'R)$. ^{*c*}log *P*. ^{*d*}Volume ratio of ascorbic acid solutions/DPPH solution 3:1 instead of 1:1. ^{*c*}Not tested.



Figure 2. Lipophilicity determination of (7'S)-esters of hydroxymatairesinol (1).

(200 μ M) and of the assayed products. A time-course study on 1 showed that an interval of 1 h was sufficient for incubation of all samples

The results for the DPPH assay are illustrated in Figure 3. All compounds exhibited good to excellent scavenging of DPPH radicals when compared to standards. The inhibition curve profiles of 1 and its derivatives 3-5 were in between those of ascorbic acid and BHT. Compound 1 reacted as instantaneously as ascorbic acid at lower concentrations, but full inhibition was not obtained until after a 1 h reaction. Esters 3-5 exhibited a slightly lower activity than 1, with a similar inhibition profile, in a comparable manner to BHT. At lower concentrations, the DPPH radical-scavenging activities of esters 3-5 were similar to that of the lipophilic standard α -tocopherol.

The IC₅₀ values for each compound and standard were between 20 and 25 μ M, except for BHT (34.0 μ M) (Table 2). Surprisingly, the IC₅₀ value for 1 (20.0 μ M) was slightly lower than for ascorbic acid (20.3 μ M) under the conditions of the test. Ascorbic acid was tested again in literature conditions, and the result confirmed the validity of the test (12.6 μ M).³⁶ Incorporating an ester chain on 1 increased the IC₅₀ value to around 4–5 μ M, but the antioxidant activities of 3–5 were still kept high. Thus, the ester family exhibited close IC₅₀ values (24.1–25.2 μ M) to that of the lipid-soluble vitamin α tocopherol (23.5 μ M).



Figure 3. Scavenging of DPPH radicals by 1 and esters 3–5. In a 2 mL reaction vial containing 1 mL of each assayed product $(2-200 \ \mu\text{M})$ in MeOH was added 1 mL of DPPH solution $(200 \ \mu\text{M})$ in MeOH, except ascorbic acid* $(0.5 \text{ mL of DPPH solution} (200 \ \mu\text{M})$ in MeOH added to 1.5 mL of ascorbic acid solution $(2-200 \ \mu\text{M})$ in MeOH).

The inhibition profiles of 1 and derivatives 3-5 were similar to that of BHT, showing a rounded curve typical of a slow action. This was also suggested by the relatively long incubation times required for lower concentration samples to achieve stability. This slow mechanism was tempered by the presence of two guaiacyl groups that reinforced strongly the antioxidant activity.

Concluding Remarks. In conclusion, a simple and straightforward strategy was designed to synthesize the C-7' ester derivatives 3–5 from hydroxymatairesinol (1). The benzyl protection of guaiacyls prevented side-reactions of translactonization into isohydroxymatairesinol and the intramolecular cyclization into conidendrin (7). Benzyl protection at room temperature with cesium carbonate and TBAI provided the dibenzylated compound 12 in high yield (96%). Once hydroxymatairesinol (1) was suitably protected, the intramolecular cyclization was inhibited and the molecule could undergo C-7' esterification (70-88% depending on the chain length) by using conventional DCCI as a coupling reagent. The benzyl deprotection was catalyzed by Pd(OH)₂ under atmospheric H_2 at room temperature (92-95%). The semisynthesis of the C-7' esters 3-5 worked efficiently under mild conditions. The three different carbon chain lengths introduced (C₇H₁₅CO, C₁₁H₂₃CO, C₁₇H₃₅CO) allowed the modulation of lipophilicity on 1. The derivatives 3-5 exhibited very high antioxidant properties (IC₅₀: 24-25 μ M) in a DPPH radicalscavenging assay when compared to the common antioxidants ascorbic acid, α -tocopherol, and BHT. Lipophilization may help solubilization of this natural hydrophilic antioxidant into lipophilic media and find industrial uses in the food, cosmetic, and pharmaceutical industries. Therefore, this work has contributed the generation of highly valuable bioactive molecules from industrial wood wastes.

EXPERIMENTAL SECTION

General Experimental Procedures. All commercially available chemicals were purchased and used as supplied by the manufacturers. Hydroxymatairesinol (1) was isolated from knotwood according to the method described in ref 16 and in the Supporting Information. GC-MS analysis was performed on a Clarus 680 gas chromatograph coupled to a Clarus SQ8 quadrupole mass spectrometer (PerkinElmer,

USA). Gas chromatography was carried out on a 5% diphenyl/95% dimethyl polysiloxane fused-silica capillary column (DB-5 ms, 30 m × 0.25 mm, 0.25 μ m film thickness, J&W Scientific, USA) with helium as carrier gas at a constant flow of 1 mL/min. Prior to analyses, samples were silvlated by addition of 80 μ L of N,O-bis(trimethylsilyl)trifluoroacetamide/trimethylsilyl chloride (99:1) and heating at 60 °C until complete solubilization. UHPLC analysis for determination of $\log K'_{w}$ values was performed on a Shimadzu 8030 apparatus equipped with an SPD-M20A diode array detector. The separations were carried out in thermostated conditions at 40 °C with a reversed-phase column (Phenomenex Luna 3 μ m C₁₈). The elution was carried out with a binary solvent system consisting of water with 0.1% formic acid and acetonitrile with 0.1% formic acid. The injection volume was fixed at 5.0 µL. Detection was carried out with a UV detector set at 254 nm and under selected ion monitoring by negative and positive mode ESIMS. The operating parameters for MS detection were as follows: nebulizing gas N2, flow 3.0 L/min, drying gas flow 15 L/min, interface voltage 4.5 kV, gas pressure 230 kPa, CDL temperature 250 °C, and block heater temperature 400 °C. The DPPH assays were conducted with a methanol solution (analytical grade) of DPPH (200 μ M). Methanol stock solutions of antioxidants were made at 1 mM. Solutions of antioxidants were obtained directly by dilution of aliquots from the stock solution (50 mL of each concentration, 2–200 μ M). The reaction was started by adding 1 mL of DPPH (200 μ M) to 1 mL of antioxidant solution. Absorbance of the reaction mixture was measured on a Shimadzu UV-2550 spectrophotometer at 517 nm. Purifications were conducted on a preparative HPLC PuriFlash 4100-250 coupled to an internal UV analyzer and a Flash-ELSD (Interchim, France). The ELSD was supplied with N2 by a Parker Domnick Hunter G3110E nitrogen gas generator. The columns were prepacked high-performance silica gel with a particle size of 30 μ m [Interchim PuriFlash PF-30SIHP-JP/25G or PF-30SIHP-JP/120G]. The crude mixtures were solubilized in the minimum of solvent (5-10 mL per g)and deposited on Merck Geduran silica gel SI60 0.063-0.200 mm (3 g per g of extract) before evaporation of the solvent. Dry loading used a Merck EasyVarioFlash EVF D17 5 g or EVF D24 30 g empty cartridge completed with sand when necessary. Melting points were measured on a digital melting point apparatus (Electrothermal, UK). FT-IR spectra were obtained on a Spectrum One spectrometer in ATR mode (PerkinElmer, USA). ¹H and ¹³C NMR spectra were recorded with an Avance DRX 400 NMR spectrometer (Bruker, Germany) at 400 and 100 MHz, respectively, and chemical shifts are reported downfield from tetramethylsilane.

Synthesis of Compound 12 (7'S-12a and 7'R-12b). To a solution of 1 (7.40 mmol, 1 equiv, 2.77 g) dissolved in acetone (70 mL) were added successively TBAI (2.22 mmol, 0.3 equiv, 820 mg) and Cs₂CO₃ (14.80 mmol, 2 equiv, 4.82 g). Benzyl bromide (22.2 mmol, 3 equiv, 2.64 mL) was then added dropwise, and the mixture stirred at room temperature for 4 h. Excess BnBr was quenched by addition of silica gel (15 g) to the crude mixture, and the volatiles were evaporated under a vacuum. The solid load was submitted to purification over silica gel (hexane/ethyl acetate, 1:1) to provide 12 as a white solid (3.94 g, 96%): mp 54–60 °C; FTIR ν_{max} 3498br w, 1760, 1591w, 1511s sh, 1452w, 1420w, 1380w, 1259s, 1224s, 1136s, 1025s cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.27–7.43 (10H, m, H-Ar), 6.42-6.82 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.14 (2H, s, H-10), 5.11 (2H, s, H-10'), 4.60 (0.6H, d, J = 6.74 Hz, H-7'a), 4.36 (0.4H, d, J = 6.78 Hz, H-7'b), 3.87-3.94 (2H, m, H-9'), 3.84 (2H, s, 10.00)OCH₃a), 3.82 (2H, s, OCH₃a), 3.81 (1H, s, OCH₃b), 3.80 (1H, s, OCH₃b), 2.85-3.09 (2H, m, H-7), 2.67-2.81 (1H, m, H-8), 2.48-2.63 (1H, m, H-8'), 1.98 (0.6H, s, OH-7'a), 1.91 (0.4H, s, OH-7'b); ^{13}C NMR (CDCl_3, 100 MHz) δ 179.2 (C, C-9a), 179.0 (C, C-9b), 149.8 (C, C-3a), 149.7 (C, C-3b), 149.6 (C, C-3'b), 149.4 (C, C-3'a), 147.9 (C, C-4'a), 147.8 (C, C-4'b), 146.9 (C, C-4b), 146.8 (C, C-4a), 137.1 (C, C-11'a), 137.0 (C, C-11'b), 136.8 (C, C-11), 134.7 (C, C-1'b), 134.6 (C, C-1'a), 130.7 (C, C-1a), 130.6 (C, C-1b), 128.5 (CH, C-13', C-15'), 128.4 (CH, C-13, C-15), 127.8 (CH, C-14), 127.7 (CH, C-14'), 127.2 (CH, C-12'a, C-16'a), 127.1 (CH, C-12'b, C-16'b), 127.1 (CH, C-12, C-16), 121.7 (CH, C-6a), 121.2 (CH, C-6b), 118.1 (CH, C-6'), 113.9 (CH, C-2b), 113.8 (CH, C-2a), 113.7 (CH,

C-5a), 113.6 (CH, C-5b), 113.3 (CH, C-5'a), 112.7 (CH, C-5'b), 109.5 (CH, C-2'a), 109.4 (CH, C-2'b), 74.8 (CH, C-7'a), 73.8 (CH, C-7'b), 71.0 (CH₂, C-10), 70.9 (CH₂, C-10'a), 70.8 (CH₂, C-10'b), 68.4 (CH₂, C-9'a), 68.0 (CH₂, C-9'b), 55.9 (CH₃, OCH₃b), 55.8 (CH₃, OCH₃a), 46.0 (CH, C-8'b), 45.0 (CH, C-8'a), 43.4 (CH, C-8a), 43.3 (CH, C-8b), 34.8 (CH₂, C-7a), 34.6 (CH₂, C-7b); anal. C 73.63, H 6.18%, calcd for $C_{34}H_{34}O_{6}$, C 73.81, H 6.35%.

General Procedures for C-7' Esterification (Compounds 14-17). A. Procedure with Acetic Anhydride. Compound 14 (7'S-14a and 7'R-14b). To a solution of 12 (216 μ mol, 1 equiv, 120 mg) and NaHCO₃ (433 µmol, 2 equiv, 36 mg) in toluene (3 mL) was added dropwise acetic anhydride (1.08 mmol, 5 equiv, 102 μ L), and the mixture heated to reflux of toluene for 1 h. After filtration, the filtrate was evaporated under vacuum and taken into CH₂Cl₂ (20 mL). The organic phase was washed with saturated aqueous NaCl solution $(3 \times$ 5 mL), dried over MgSO₄, and evaporated under a vacuum to give 14 as an off-white powder (115 mg, 89% yield) after purification over silica gel (hexane/ethyl acetate, 4:6): mp 61–63 °C; FTIR ν_{max} 2928w, 2851w, 1768s, 1739s, 1592w, 1513s sh, 1454, 1422w, 1419w, 1262s, 1228s, 1141s, 1024s cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.27–7.44 (10H, m, H-Ar), 6.43-6.90 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.76 (0.69H, d, J = 6.63 Hz, H-7'a), 5.55 (0.31H, d, J = 7.49 Hz, H-7'b), 5.12 (4H, s, H-10, H-10'), 3.83-4.18 (2H, m, H-9'), 3.81 (3H, s, OCH₃), 3.79 (3H, s, OCH₃), 2.52-3.15 (4H, m, H-7, H-8, H-8'), 2.05 (1.9H, s, CH₃a), 2.04 (1.1H, s, CH₃b); ¹³C NMR (CDCl₃, 100 MHz) δ 178.1 (C, C-9a), 178.0 (C, C-9b), 169.7 (C, C-1"a), 169.6 (C, C-1"b), 149.7 (C, C-3b), 149.6 (C, C-3a, C-3'b), 149.5 (C, C-3'a), 148.3 (C, C-4'a), 148.2 (C, C-4'b), 147.1 (C, C-4b), 147.0 (C, C-4a), 137.0 (C, C-11'), 136.7 (C, C-11), 130.4 (C, C-1'b), 130.1 (C, C-1'a), 130.0 (C, C-1a), 129.9 (C, C-1b), 128.5 (CH, C-13', C-15'), 128.4 (CH, C-13, C-15), 127.8 (CH, C-14), 127.7 (CH, C-14'), 127.3 (CH, C-12'a, C-16'a), 127.2 (CH, C-12'b, C-16'b), 127.1 (CH, C-12, C-16), 121.5 (CH, C-6a), 121.3 (CH, C-6b), 118.6 (CH, C-6'), 113.9 (CH, C-2), 113.7 (CH, C-5), 113.1 (CH, C-5'a), 112.7 (CH, C-5'b), 110.1 (CH, C-2'), 75.9 (CH, C-7'a), 75.4 (CH, C-7'b), 71.0 (CH₂, C-10), 70.8 (CH₂, C-10'), 67.8 (CH₂, C-9'b), 67.7 (CH₂, C-9'a), 56.0 (CH₃, OCH₃a), 55.9 (CH₃, OCH₃b), 55.8 (CH₃, OCH₃), 43.8 (CH, C-8'), 43.5 (CH, C-8b), 43.3 (CH, C-8a), 34.8 (CH₂, C-7a), 34.2 (CH₂, C-7b), 21.0 (CH₃, CH₃b), 20.9 (CH₃, CH₃a); anal. C 72.21, H, 6.34%, calcd for C₃₆H₃₆O₈, C 72.47, H 6.08%.

B. Procedure with DAST (Compound 15). A solution of octanoic acid (216 μ mol, 1.2 equiv, 34.3 μ L) in CH₂Cl₂ (1.5 mL) was cooled to 0 °C before dropwise addition of DAST (216 μ mol, 1.2 equiv, 30 μ L). After 30 min, the mixture was transferred through a cannula to a solution of compound 12 (180 μ mol, 1 equiv, 100 mg) and DMAP (180 μ mol, 1 equiv, 22 mg) in CH₂Cl₂ (1.5 mL). The mixture was stirred at rt for an additional 90 min before quenching and purification over silica gel (hexane/ethyl acetate, 6:4) to provide 15 as a white solid (84 mg, 68%).

C. Procedure with Acyl Chlorides (Compounds 15 and 16). To a solution of 12 (180 μ mol, 1 equiv, 100 mg) in acetonitrile (4 mL) was added DMAP (216 μ mol, 1.2 equiv, 26 mg), and the mixture was cooled to 0 °C before dropwise addition of acyl chloride (216 μ mol, 1.2 equiv). The mixture was stirred at 80 °C for 24 h. After evaporation of the volatiles, the residue was dissolved in CH₂Cl₂ (20 mL) and washed with saturated aqueous NaCl solution (3 × 5 mL) to afford after evaporation under vacuum the desired compound as a white solid (15: 52%, 16: 46%).

D. General Procedure of Esterification with DCCI (Compounds 15-17). To a solution of 12 (2.70 mmol, 1 equiv, 1.5 g) in acetonitrile (35 mL) were added successively DMAP (3.52 mmol, 1.3 equiv, 430 mg), a fatty acid (3.52 mmol, 1.3 equiv), and DCCI (3.52 mmol, 1.3 equiv, 725 mg). The mixture was stirred at 80 °C for 4 h. Silica gel (20 g) was added to the crude mixture, and the solid loading was purified over silica gel (hexane/ethyl acetate, 8:2 to 4:6) to provide the esters 15–17 as white solids (70–88%) (15: 88% yield, 16: 77% yield, 17: 70% yield).

Compound **15** (7'S-**15a** and 7'R-**15b**: white solid, 88%, mp 69–71 °C; FTIR ν_{max} 3497w, 3372br w, 2920s, 2850s sh, 1739, 1610w, 1515s sh, 1468, 1370w, 1266, 1213, 1157s, 1105, 1072, 1038 cm⁻¹; ¹H NMR

(CDCl₂, 400 MHz) δ 7.28-7.46 (10H, m, H-Ar), 6.47-6.85 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.82 (0.67H, d, J = 6.22 Hz, H-7'a), 5.60 (0.33H, d, J = 7.33 Hz, H-7'b), 5.11 (4H, br s, H-10, H-10'), 3.88-4.17 (2H, m, H-9'), 3.83 (2H, s, OCH₃a), 3.80 (4H, br s, OCH₃b, OCH₃), 2.61-3.02 (4H, m, H-7, H-8, H-8'), 2.40 (1.25H, t, J = 7.36 Hz, H-2"a), 2.33 (0.75H, t, J = 7.23 Hz, H-2"b), 1.64 (2H, m, H-3"), 1.30 (8H, m, 4 CH₂), 0.91 (3H, m, CH₃); ¹³C NMR (CDCl₃, 100 MHz) δ 177.7 (C, C-9a), 177.6 (C, C-9b), 172.0 (C, C-1"a), 171.9 (C, C-1"b), 149.3 (C, C-3b, C-3'b), 149.2 (C, C-3a, C-3'a), 147.8 (C, C-4'), 146.7 (C, C-4), 136.8 (C, C-11'), 136.5 (C, C-11), 130.4 (C, C-1'b), 130.0 (C, C-1'a), 129.9 (C, C-1a), 129.8 (C, C-1b), 128.0 (CH, C-13', C-15'), 127.9 (CH, C-13, C-15), 127.4 (CH, C-14), 127.3 (CH, C-14'), 126.9 (CH, C-12'a, C-16'a), 126.9 (CH, C-12'b, C-16'b), 126.8 (CH, C-12, C-16), 121.1 (CH, C-6a), 121.0 (CH, C-6b), 118.2 (CH, C-6'b), 118.0 (CH, C-6'a), 113.5 (CH, C-2), 113.3 (CH, C-5b), 113.2 (CH, C-5a), 112.8 (CH, C-5'a), 112.5 (CH, C-5'b), 109.7 (CH, C-2'b), 109.5 (CH, C-2'a), 75.3 (CH, C-7'a), 74.8 (CH, C-7'b), 70.5 (CH₂, C-10), 70.4 (CH₂, C-10'), 67.5 (CH₂, C-9'a), 67.4 (CH₂, C-9'b), 55.5 (CH₃, OCH₃a), 55.4 (CH₃, OCH₃b), 55.3 (CH₃, OCH₃), 43.5 (CH, C-8'b), 43.3 (CH, C-8'a), 43.1 (CH, C-8b), 43.0 (CH, C-8a), 34.4 (CH₂, C-7b), 33.9 (CH₂, C-7a), 33.8 (CH₂, C-2"b), 31.1 (CH₂, C-2"a), 28.6 (CH₂, C-4"a, C-5"a), 28.5 (CH₂, C-4"b, C-5"b), 28.4 (CH₂, C-6"a), 28.3 (CH₂, C-6"b), 24.5 (CH₂, C-3"b), 24.4 (CH₂, C-3"a), 22.1 (CH₂, C-7"), 13.6 (CH₃, C-8"); anal. C 74.13, H 7.21%, calcd for $\rm C_{42}H_{48}O_8$, C 74.09, H 7.11%.

Compound 16 (7'S-16a and 7'R-16b): white solid, 77%, mp 76-78 °C; FTIR $\nu_{\rm max}$ 2918, 2849, 1780s, 1737s, 1591w, 1518s sh, 1454, 1421w, 1365w, 1258s, 1238s, 1158s, 1137s, 1029s cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) & 7.28-7.44 (10H, m, H-Ar), 6.43-6.81 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.79 (0.69H, d, J = 6.39 Hz, H-7'a), 5.57 (0.31H, d, J = 7.35 Hz, H-7'b), 5.11 (4H, br s, H-10, H-10'), 3.82-4.18 (2H, m, H-9'), 3.82 (2H, s, OCH₃a), 3.80 (3H, br s, OCH₂), 3.79 (1H, s, OCH₂b), 2.59-3.06 (4H, m, H-7, H-8, H-8'), 2.37 (1.30H, t, J = 6.99 Hz, H-2"a), 2.31 (0.70H, t, J = 7.17 Hz, H-2"b), 1.61 (2H, m, H-3"), 1.27 (16H, m, 8 CH₂), 0.89 (3H, t, J = 6.81 Hz, CH₃); ¹³C NMR (CDCl₃, 100 MHz) δ 178.0 (C, C-9a), 177.9 (C, C-9b), 172.4 (C, C-1"a), 172.3 (C, C-1"b), 149.6 (C, C-3'b), 149.5 (C, C-3b), 149.5 (C, C-3a), 149.4 (C, C-3'a), 148.1 (C, C-4'a), 148.0 (C, C-4'b), 147.0 (C, C-4b), 146.9 (C, C-4a), 137.0 (C, C-11'), 136.7 (C, C-11), 130.6 (C, C-1'b), 130.1 (C, C-1'a), 130.0 (C, C-1a), 129.9 (C, C-1b), 128.4 (CH, C-13', C-15'), 128.3 (CH, C-13, C-15), 127.7 (CH, C-14), 127.6 (CH, C-14'), 127.1 (CH, C-12'a, C-16'a), 127.0 (CH, C-12'b, C-16'b), 126.9 (CH, C-12, C-16), 121.4 (CH, C-6a), 121.2 (CH, C-6b), 118.4 (CH, C-6'b), 118.3 (CH, C-6'a), 113.8 (CH, C-2), 113.6 (CH, C-5'b), 113.5 (CH, C-5'a), 113.0 (CH, C-5a), 112.7 (CH, C-5b), 109.9 (CH, C-2'b), 109.8 (CH, C-2'a), 75.5 (CH, C-7'a), 75.0 (CH, C-7'b), 70.8 (CH₂, C-10), 70.7 (CH₂, C-10'), 67.8 (CH₂, C-9'a), 67.7 (CH₂, C-9'b), 55.8 (OCH₃a), 55.7 (OCH₃b), 55.6 (OCH₃), 43.8 (CH, C-8'b), 43.6 (CH, C-8'a), 43.4 (CH, C-8b), 43.2 (CH, C-8a), 34.7 (CH₂, C-7b), 34.2 (CH₂, C-7a), 34.1 (CH₂, C-2"b), 34.0 (CH₂, C-2"a), 31.7 (CH₂, C-10"), 29.4 (2 CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.0 (CH₂), 28.9 (CH₂), 24.7 (CH₂, C-3"), 22.5 (CH₂) C-11"), 14.0 (CH₃b), 13.9 (CH₃a); anal. C 74.64, H 7.88%, calcd for С₄₆Н₅₆О₈, С 74.97, Н 7.66%.

Compound 17 (7'S-17a and 7'R-17b): white solid, 70%, mp 93-95 °C; FTIR v_{max} 2917, 2850, 1780, 1734, 1590w, 1518s sh, 1465, 1454, 1384w, 1259s, 1232s, 1156s, 1141s, 1026s cm⁻¹; ¹H NMR (CDCl₂, 400 MHz) δ 7.26–7.45 (10H, m, H-Ar), 6.45–6.82 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.81 (0.68H, d, J = 6.25 Hz, H-7'a), 5.59 (0.32H, d, J = 7.34 Hz, H-7'b), 5.11 (4H, br s, H-10, H-10'), 3.88-4.17 (2H, m, H-9'), 3.82 (2H, s, OCH₃a), 3.80 (1H, s, OCH₃b), 3.80 (2H, s, OCH₃a), 3.79 (1H, s, OCH₃b), 2.60-3.02 (4H, m, H-7, H-8, H-8'), 2.39 (1.30H, t, J = 7.37 Hz, H-2"a), 2.32 (0.70H, t, J =7.25 Hz, H-2"b), 1.64 (2H, m, H-3"), 1.30 (28H, m, 14 CH₂), 0.92 $(3H, t, J = 6.78 \text{ Hz}, \text{CH}_3);$ ¹³C NMR (CDCl₃, 100 MHz) δ 177.9 (C, C-9a), 177.7 (C, C-9b), 172.1 (C, C-1"a), 172.0 (C, C-1"b), 149.5 (C, C-3'b), 149.4 (C, C-3b), 149.4 (C, C-3a), 149.3 (C, C-3'a), 147.9 (C, C-4'), 146.9 (C, C-4b), 146.8 (C, C-4a), 136.9 (C, C-11'), 136.6 (C, C-11), 130.5 (C, C-1'b), 130.0 (C, C-1'a), 129.9 (C, C-1a), 129.8 (C, C-1b), 128.2 (CH, C-13', C-15'), 128.1 (CH, C-13, C-15), 127.5

(CH, C-14), 127.4 (CH, C-14'), 127.0 (CH, C-12'a, C-16'a), 126.9 (CH, C-12'b, C-16'b), 126.8 (CH, C-12, C-16), 121.2 (CH, C-6a), 121.1 (CH, C-6b), 118.3 (CH, C-6'b), 118.2 (CH, C-6'a), 113.6 (CH, C-2), 113.4 (CH, C-5'b), 113.3 (CH, C-5'a), 112.9 (CH, C-5a), 112.6 (CH, C-5b), 109.8 (CH, C-2'b), 109.7 (CH, C-2'a), 75.4 (CH, C-7'a), 74.9 (CH, C-7'b), 70.7 (CH₂, C-10), 70.5 (CH₂, C-10'), 67.6 (CH₂, C-9'), 55.6 (CH₃, OCH₃a), 55.5 (CH₃, OCH₃b), 55.4 (CH₃, OCH₃), 43.7 (CH, C-8'b), 43.4 (CH, C-8'a), 43.2 (CH, C-8b), 43.1 (CH, C-8a), 34.6 (CH₂, C-7b), 34.0 (CH₂, C-7a), 33.9 (CH₂, C-2"), 31.6 (CH₂, C-16"), 29.4 (5 CH₂), 29.3 (2 CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.0 (2 CH₂), 28.8 (CH₂), 24.6 (CH₂, C-3"), 22.4 (CH₂, C-17"), 13.8 (CH₃); anal. C 75.91, H 8.48%, calcd for C₅₂H₆₈O₈, C 76.06, H 8.35%.

General Procedure for Deprotection of Benzyl Groups (Compounds 3–5). To a solution of esters 15-17 (~1 mmol, 1 equiv, 750 mg) in ethanol (30 mL) was added Pd(OH)₂ 20% (0.3 equiv, ~200 mg), and the mixture was vigorously stirred at rt for 2–2.5 h. After filtration over Celite, the filtrate was purified over silica gel (hexane/ethyl acetate, 8:2 to 4:6) to provide, respectively, 3-5 (92–95%).

Compound 3 (7'S-3a and 7'R-3b): colorless, viscous liquid, 95%; FTIR $\nu_{\rm max}$ 3393br, 2956, 2937, 2857, 1740, 1613w, 1516s sh, 1457w, 1432w, 1369w, 1270, 1237, 1157, 1121, 1064, 1031 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) & 6.37-6.81 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 5.88 (2H, br s, OH-4, OH-4'), 5.77 (0.75H, d, J = 6.13 Hz, H-7'a), 5.51 (0.25H, d, J = 7.8 Hz, H-7'b), 3.87-4.17 (2H, m, H-9'), 3.76 (2H, s, OCH₃a), 3.75 (3H, br s, OCH₃), 3.73 (1H, s, OCH₃b), 2.52-2.96 (4H, m, H-7, H-8, H-8'), 2.35 (1.43H, t, J = 7.52 Hz, H-2"a), 2.27 (0.57H, t, J = 7.76 Hz, H-2"b), 1.57 (2H, m, H-3"), 1.24 (8H, m, 4 CH₂), 0.83 (3H, m, CH₃); ¹³C NMR (CDCl₃, 100 MHz) δ 178.4 (C, C-9a), 178.2 (C, C-9b), 172.6 (C, C-1"a), 172.4 (C, C-1"b), 146.7 (C, C-3), 146.6 (C, C-3'a), 146.5 (C, C-3'b), 145.7 (C, C-4'b), 145.6 (C, C-4'a), 144.5 (C, C-4b), 144.4 (C, C-4a), 129.4 (C, C-1'b), 128.9 (C, C-1'a), 128.8 (C, C-1a), 128.7 (C, C-1b), 122.1 (CH, C-6a), 121.9 (CH, C-6b), 119.5 (CH, C-6'b), 118.8 (CH, C-6'a), 114.4 (CH, C-2a), 114.3 (CH, C-2b), 114.0 (CH, C-5'a), 113.9 (CH, C-5'b), 111.6 (CH, C-5a), 111.2 (CH, C-5b), 108.8 (CH, C-2'), 75.8 (CH, C-7'a), 75.3 (CH, C-7'b), 68.0 (CH₂, C-9'), 55.6 (CH₃, OCH₃a), 55.5 (CH₃, OCH₃), 55.5 (CH₃, OCH₃b), 43.8 (CH, C-8'b), 43.7 (CH, C-8'a), 43.6 (CH, C-8b), 43.3 (CH, C-8a), 34.8 (CH₂, C-7b), 34.3 (CH₂, C-7a), 34.2 (CH₂, C-2"a), 34.1 (CH₂, C-2"b), 31.41 (CH₂, C-6"a), 31.4 (CH₂, C-6"b), 28.9 (CH₂a), 28.8 (CH₂b), 28.7 (CH₂a), 28.6 (CH₂b), 24.7 (CH₂b), 24.6 (CH₂a), 22.4 (CH₂, H-7"), 14.0 (CH₃b), 13.9 (CH₃a); anal. C 67.11, H 7.30%, calcd for C₂₈H₃₆O₈, C 67.18. H 7.25.

Compound 4 (7'S-4a and 7'R-4b): colorless, viscous liquid, 92%; FTIR $\nu_{\rm max}$ 3425br, 2926, 2853, 1768, 1742, 1607w, 1516s sh, 1465w, 1432w, 1376w, 1270s, 1238, 1152s, 1123, 1028s cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 6.43–6.81 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 6.01 (1H, br s, OH-4'), 5.88 (1H, br s, OH-4), 5.77 (0.84H, d, J = 6.04 Hz, H-7'a), 5.51 (0.16H, d, J = 7.96 Hz, H-7'b), 3.89-4.17 (2H, m, H-9'), 3.75 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 2.52-2.95 (4H, m, H-7, H-8, H-8'), 2.34 (1.64H, t, J = 7.51 Hz, H-2"a), 2.27 (0.36H, t, J = 7.24 Hz, H-2"b), 1.59 (2H, m, H-3"), 1.24 (16H, m, 8 CH₂), 0.85 (3H, t, J = 6.77 Hz, CH₃); ¹³C NMR (CDCl₃, 100 MHz) δ 178.4 (C, C-9a), 178.2 (C, C-9b), 172.6 (C, C-1"a), 172.5 (C, C-1"b), 146.7 (C, C-3), 146.6 (C, C-3'a), 146.5 (C, C-3'b), 145.7 (C, C-4'b), 145.6 (C, C-4'a), 144.5 (C, C-4b), 144.4 (C, C-4a), 129.3 (C, C-1'b), 128.9 (C, C-1'a), 128.7 (C, C-1a), 128.6 (C, C-1b), 122.1 (CH, C-6a), 121.9 (CH, C-6b), 119.4 (CH, C-6'b), 118.7 (CH, C-6'a), 114.4 (CH, C-2a), 114.3 (CH, C-2b), 114.0 (CH, C-5'a), 113.9 (CH, C-5'b), 111.5 (CH, C-5a), 111.2 (CH, C-5b), 108.8 (CH, C-2'), 75.7 (CH, C-7'a), 75.3 (CH, C-7'b), 68.0 (CH₂, C-9'), 55.6 (CH₃, OCH₃a), 55.5 (CH₃, OCH₃, OCH₃b), 43.8 (CH, C-8'b), 43.7 (CH, C-8'a), 43.6 (CH, C-8b), 43.3 (CH, C-8a), 34.8 (CH₂, C-7b), 34.3 (CH₂, C-7a), 34.2 (CH₂, C-2"a), 34.1 (CH₂, C-2"b), 31.6 (CH₂, C-10"), 29.4 (2 CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.0 (CH₂), 28.9 (CH₂), 24.7 (CH₂) C-3"), 22.5 (CH₂, C-11"), 13.9 (CH₃); anal. C 69.25, H 8.14%, calcd for C₃₂H₄₄O₈, C 69.04, H 7.97%.

Journal of Natural Products

Compound 5 (7'S-5a and 7'R-5b): colorless, viscous liquid, 93%; FTIR ν_{max} 3434br, 2925, 2851, 1763, 1738, 1604w, 1516s sh, 1464, 1374w, 1237, 1272, 1154s, 1121, 1030s cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 6.43-6.80 (6H, m, H-2, H-5, H-6, H-2', H-5', H-6'), 6.03 (1H, br s, OH-4'), 5.89 (1H, br s, OH-4), 5.77 (0.86H, d, J = 5.97 Hz, H-7'a), 5.51 (0.14H, d, J = 7.97 Hz, H-7'b), 3.89–4.14 (2H, m, H-9'), 3.74 (3H, br s, OCH₃), 3.73 (3H, br s, OCH₃), 2.52-2.94 (4H, m, H-7, H-8, H-8'), 2.34 (1.65H, t, J = 7.49 Hz, H-2"a), 2.27 (0.35H, t, J = 7.69 Hz, H-2"b), 1.58 (2H, m, H-3"), 1.22 (28H, m, 14 CH₂), 0.85 (3H, t, J = 6.73 Hz, CH₃); ¹³C NMR (CDCl₃, 100 MHz) δ 178.3 (C, C-9a), 178.2 (C, C-9b), 172.6 (C, C-1"a), 172.4 (C, C-1"b), 146.7 (C, C-3), 146.6 (C, C-3'b), 146.5 (C, C-3'a), 145.7 (C, C-4'b), 145.6 (C, C-4'a), 144.5 (C, C-4b), 144.4 (C, C-4a), 129.3 (C, C-1'b), 128.9 (C, C-1'a), 128.7 (C, C-1a), 128.6 (C, C-1b), 122.0 (CH, C-6a), 121.9 (CH, C-6b), 119.4 (CH, C-6'b), 118.7 (CH, C-6'a), 114.4 (CH, C-2a), 114.3 (CH, C-2b), 114.0 (CH, C-5'a), 113.9 (CH, C-5'b), 111.5 (CH, C-5a), 111.2 (CH, C-5b), 108.8 (CH, C-2'), 75.7 (CH, C-7'a), 75.3 (CH, C-7'b), 68.0 (CH₂, C-9'), 55.5 (CH₃, OCH₃), 55.4 (CH₃, OCH₃), 43.8 (CH, C-8'b), 43.7 (CH, C-8'a, C-8b), 43.3 (CH, C-8a), 34.8 (CH₂, C-7b), 34.3 (CH₂, C-7a), 34.2 (CH₂, C-2"a), 34.1 (CH₂, C-2"b), 31.7 (CH₂, C-16"), 29.5 (5 CH₂), 29.4 (2 CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.0 (CH₂), 28.9 (CH₂), 24.7 (CH₂, C-3"), 22.4 (CH₂, C-17"), 14.0 (CH₃b), 13.9 (CH₃a); anal. C 71.39, H 8.89%, calcd for C38H56O8, C 71.22, H 8.81%.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnat-prod.6b01124.

Experimental for compounds **1**, **7**, **10**, and **13**; IR spectra; ¹H and ¹³C NMR spectra; additional lipophilicity data (PDF)

AUTHOR INFORMATION

Corresponding Author

*Tel (C. Gérardin): +33 (0)3 72 74 52 34. E-mail: Christine. Gerardin@univ-lorraine.fr.

ORCID 🔍

Thomas Moraux: 0000-0001-9615-4618

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors acknowledge FEDER and BPI for financial support, and Norske Skog (Golbey, France) for providing wood samples. LERMAB was supported by a grant overseen by the French National Research Agency (ANR) as part of the "Investissements d'Avenir" program (ANR-11-LABX-0002-01, Lab of Excellence ARBRE).

REFERENCES

(1) Kim, C. S.; Kwon, O. W.; Kim, S. Y.; Lee, K. R. J. Nat. Prod. 2013, 76, 2131–2135.

(2) Lee, D.-Y.; Seo, K.-H.; Jeong, R.-H.; Lee, S.-M.; Kim, G.-S.; Noh, H.-J.; Kim, S.-Y.; Kim, G.-W.; Kim, J.-Y.; Baek, N.-I. *Molecules* **2013**, *18*, 41–49.

(3) Araújo, I.; Silva, D.; do Carmo de Alustau, M.; Dias, K.; Cavalcante, K.; Veras, R.; Barbosa-Filho, J.; Neto, M.; Bendhack, L.; de Azevedo Correia, N.; Almeida de Medeiros, I. *Molecules* **2014**, *19*, 6863–6876.

(4) Chun, J. N.; Cho, M.; So, I.; Jeon, J.-H. Fitoterapia 2014, 97, 224–233.

(5) Cui, H.; Xu, B.; Wu, T.; Xu, J.; Yuan, Y.; Gu, Q. J. Nat. Prod. 2014, 77, 100–110.

(6) Li, X.-N.; Pu, J.-X.; Du, X.; Yang, L.-M.; An, H.-M.; Lei, C.; He, F.; Luo, X.; Zheng, Y.-T.; Lu, Y.; Xiao, W.-L.; Sun, H.-D. *J. Nat. Prod.* **2009**, *72*, 1133–1141.

(7) Mukhija, M.; Dhar, K. L.; Kalia, A. N. J. Ethnopharmacol. 2014, 152, 106–112.

(8) Suh, W. S.; Subedi, L.; Kim, S. Y.; Choi, S. U.; Lee, K. R. Bioorg. Med. Chem. Lett. 2016, 26, 1877.

(9) Adfa, M.; Rahmad, R.; Ninomiya, M.; Yudha, S. S.; Tanaka, K.; Koketsu, M. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 761–764.

(10) Teponno, R. B.; Kusari, S.; Spiteller, M. Nat. Prod. Rep. 2016, 33, 1044-1092.

(11) Willför, S.; Nisula, L.; Hemming, J.; Reunanen, M.; Holmbom, B. *Holzforschung* **2004**, *58*, 335–344.

(12) Willför, S.; Nisula, L.; Hemming, J.; Reunanen, M.; Holmbom, B. *Holzforschung* **2004**, *58*, 650–659.

(13) Smeds, A. I.; Češková, I.; Eklund, P. C.; Willför, S. M. Holzforschung 2012, 66, 553-567.

(14) Kebbi-Benkeder, Z.; Colin, F.; Dumarcay, S.; Gerardin, P. Ann. For. Sci. 2015, 72, 277–284.

(15) Eklund, P. C.; Sundell, F. J.; Smeds, A. I.; Sjoholm, R. E. Org. Biomol. Chem. 2004, 2, 2229–2235.

(16) Extractions were conducted through a sequential maceration in ethanol (3×2 h) under vigorous stirring, to recover up to 12.5% of the extract based on the dry weight of sawdust (ca. 85% of lignans in the ethanolic extract). Large-scale purification (>10 g) was carried out by preparative HPLC in a two-step process to provide up to 30% of 1 at a purity of higher than 95%.

(17) Appendino, G.; Minassi, A.; Daddario, N.; Bianchi, F.; Tron, G. C. Org. Lett. **2002**, *4*, 3839–3841.

(18) Fletcher, S. Org. Chem. Front. 2015, 2, 739-752.

(19) Swamy, K. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. *Chem. Rev.* **2009**, *109*, 2551–2651.

(20) Freudenberg, K.; Knof, L. Chem. Ber. 1957, 90, 2857-2869.

(21) Hodgson, D. M.; Talbot, E. P. A.; Clark, B. P. Org. Lett. 2011, 13, 2594-2597.

(22) Richter, D.; Hampel, N.; Singer, T.; Ofial, A. R.; Mayr, H. Eur. J. Org. Chem. 2009, 69, 3203-3211.

(23) Aparicio-Soto, M.; Sánchez-Fidalgo, S.; González-Benjumea, A.; Maya, I.; Fernández-Bolaños, J. G.; Alarcón-de-la-Lastra, C. J. Agric. Food Chem. **2015**, 63, 836–846.

(24) Adams, D. R.; Abraham, A.; Asano, J.; Breslin, C.; Dick, C. A. J.; Ixkes, U.; Johnston, B. F.; Johnston, D.; Kewnay, J.; Mackay, S. P.; MacKenzie, S. J.; McFarlane, M.; Mitchell, L.; Spinks, D.; Takano, Y. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6579–6583.

(25) Singh, A. S.; Shendage, S. S.; Nagarkar, J. M. Tetrahedron Lett. 2014, 55, 7243–7246.

(26) Cardinal, S.; Voyer, N. *Tetrahedron Lett.* **2013**, *54*, 5178–5180. (27) Lugemwa, F.; Shaikh, K.; Hochstedt, E. *Catalysts* **2013**, *3*, 954–965.

(28) Tamaian, R.; Moţ, A.; Silaghi-Dumitrescu, R.; Ionuţ, I.; Stana, A.; Oniga, O.; Nastasă, C.; Benedec, D.; Tiperciuc, B. *Molecules* **2015**, 20, 22188–22201.

(29) Barton, P.; Riley, R. J. Drug Discovery Today 2016, 21, 72-81.

(30) Maftei, C. V.; Fodor, E.; Jones, P. G.; Daniliuc, C. G.; Franz, M. H.; Kelter, G.; Fiebig, H.-H.; Tamm, M.; Neda, I. *Tetrahedron* **2016**, 72, 1185–1199.

(31) Fernandez-Pastor, I.; Fernandez-Hernandez, A.; Rivas, F.; Martinez, A.; Garcia-Granados, A.; Parra, A. J. Nat. Prod. 2016, 79, 1737–1745.

(32) Henchoz, Y.; Bard, B.; Guillarme, D.; Carrupt, P.-A.; Veuthey, J.-L.; Martel, S. Anal. Bioanal. Chem. **2009**, 394, 707–729.

(33) Rutkowska, E.; Pajak, K.; Fau-Jozwiak, K.; Jozwiak, K. Acta Polym. Pharm. 2013, 70, 3–18.

(34) Henchoz, Y.; Guillarme, D.; Martel, S.; Rudaz, S.; Veuthey, J.-L.; Carrupt, P.-A. Anal. Bioanal. Chem. 2009, 394, 1919–1930.

(35) Guillot, A.; Henchoz, Y.; Moccand, C.; Guillarme, D.; Veuthey,

J.-L.; Carrupt, P.-A.; Martel, S. Chem. Biodiversity **2009**, *6*, 1828–1836. (36) Sharma, O. P.; Bhat, T. K. Food Chem. **2009**, *113*, 1202–1205.